This lecture was part of a CME accredited symposium; SGLT2 inhibition, diabetes and CVD: Where does this fit in CV risk management? held at ESc 2016 in Rome

Educational information

Educational objectives of this symposium were to:

• Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
• Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
• Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes-
• Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
• Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients

CME accreditation

This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

Professor John Deanfield, MD - Professor of Cardiology - Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom

Funding

Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Also watch lecture: Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift? by prof John McMurray, MD University of Glasgow United Kingdom Also watch lecture: Overview of SGLT-2 inhibitors in T2DM management: current position & future promise by prof Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA